MagSense™ technology is based on superparamagnetic relaxometry – the ability to detect the small magnetic field released by tiny nanoparticles after they have been briefly magnetized, i.e. when they “relax”. Learn More
Specialized MagSense™ nanoparticles are coated with tumor targeting antibodies and can be administered by simple intravenous injection. Injected nanoparticles circulate through normal blood flow and can bind to the target cell because of the molecular attraction of the antibody. Learn More
The highly sensitive detectors used in the MagSense™ instrument allow for unprecedented sensitivity of detection and the precise localization of the bound nanoparticles. Learn More
The MagSense™ instrument uses highly sensitive magnetic field sensors to detect the remnant magnetic relaxation of the injected nanoparticles. MagSense™ systems are inexpensive because MagSense™ technology uses a small array of sensors for localized detection and a low magnetic field, unlike more expensive imaging technologies that require strong magnetic fields and full body scanning.
MagSense™ instruments do not require a shielded operating environment and can be installed in a standard hospital facility without the additional cost of special and expensive facility engineering.
MagSense™ nanoparticles are supplied as an injectable solution and formulated to provide optimal delivery to specific types of cancer cells.
By combining the superparamagnetic properties of our PrecisionMRX® brand of iron oxide (Fe3O4) particles with tumor targeting bio-functionality, MagSense™ technology achieves unprecedented levels of in vivo tumor detection sensitivity with tumor type specificity.
Magnetite Nanoparticle Core
Uniformly Sized Superparamagnetic Fe3O4.
Protective Polymer Coating
Monolayer provides stability in aqueous suspensions.
Stealth Coating – PolyEthylene Glycol
Minimizes opsonization in biological applications.
Provides molecular specificity for targeting cells.